JNJ-6640

• Description:

  JNJ-6640 is an inhibitor targeting mycobacterial PurF (the first enzyme in the de novo purine biosynthesis pathway) with potent anti-tuberculosis activity. JNJ-6640 exhibits bactericidal activity against Mycobacterium tuberculosis in vitro, with an MIC90 of 8.6 nM. JNJ-6640 disrupts de novo purine biosynthesis, inhibits M. tuberculosis DNA replication in vivo. JNJ-6640 exhibits anti-tuberculosis efficacy in acutely infected mice. JNJ-6640 can be used for the study of tuberculosis[1].

• UNSPSC:

  12352005

• Target:

  Bacterial

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Smiles:

  CC1=NNC(OC2=C(F)C=NC(N3C[C@H](CC3)C4=CC=NC=C4)=N2)=C1

• Molecular Formula:

  C17H17FN6O

• Molecular Weight:

  340.35

• References & Citations:

  [1]Lamprecht DA, et al. Targeting de novo purine biosynthesis for tuberculosis treatment. Nature. 2025 Aug;644 (8075) :214-220.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported